Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | YAP1 | P46937 | 3/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5353421 | 1.00 | BCL2 (0.56) | BCL2PTPN1CAPN1ATMPPARG | |
| SCHEMBL272162 | 1.00 | BCL2 (0.56) | BCL2PTPN1CAPN1ATMPPARG | |
| SCHEMBL15565812 | 0.91 | RXRA (0.53) | BCL2PTPN1CAPN1PPARGHDAC8 | |
| SCHEMBL390555 | 0.89 | ATM (0.62) | CAPN1ATMCTSBCTSK | |
| SCHEMBL7094 | 0.89 | ATM (0.62) | CAPN1ATMCTSBCTSK | |
| SCHEMBL1094506 | 0.89 | ATM (0.62) | CAPN1ATMCTSBCTSK | |
| SCHEMBL14423620 | 0.89 | PTPN1 (0.55) | BCL2PTPN1ATMPPARGYAP1 | |
| SCHEMBL16991080 | 0.88 | NPC1 (0.51) | BCL2PTPN1CAPN1ITGB3ITGA2B | |
| SCHEMBL16991078 | 0.88 | NPC1 (0.51) | BCL2PTPN1CAPN1ITGB3ITGA2B | |
| SCHEMBL15414385 | 0.88 | PTPN1 (0.57) | BCL2PTPN1ATMPPARGYAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110099682-B | Coupled connector, cell binding molecule-drug conjugate containing same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20230001001-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| EP-1931657-B1 | NOVEL HIGH AFFINITY QUINOLINE-BASED KINASE LIGANDS | MERCK SHARP & DOHME (US) | 2013-12-25 | — | — | EP | disclosed |
| US-7511063-B2 | High affinity quinoline-based kinase ligands | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1931657-A2 | NOVEL HIGH AFFINITY QUINOLINE-BASED KINASE LIGANDS | SCHERING CORPORATION (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-7253194-B2 | Compounds and inhibitors of phospholipases | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-08-07 | — | — | US | disclosed |
| US-7253194-B2 | Compounds and inhibitors of phospholipases | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-08-07 | — | — | US | disclosed |
| WO-2007022241-A2 | NOVEL HIGH AFFINITY QUINOLINE-BASED KINASE LIGANDS | SCHERING CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1309552-A4 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | UNIV QUEENSLAND (AU) | 2005-07-20 | — | — | EP | disclosed |
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | QUEENSLAND, THE UNIVERSITY OF (AU) | 2004-02-19 | — | — | US | disclosed |
| EP-1309552-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002008189-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2002-01-31 | — | — | WO | disclosed |
| CN-1142830-A | Macrocyclic difluorostatone derivatives useful as antiviral agents | MERRELL DOW PHARMA (US) | 1997-02-12 | — | — | CN | disclosed |
| EP-0665215-A1 | 1,4-Diamino-2,3-dihydroxybutanes | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-08-02 | — | — | EP | disclosed |
| US-5430155-A | Viricides, treatment of AIDS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-07-04 | — | — | US | disclosed |
| US-5294720-A | Viricides | THE DUPONT MERCK PHARMACEUTICAL CO. (US) | 1994-03-15 | — | — | US | disclosed |
| WO-1991018866-A2 | 1,4-DIAMINO-2,3-DIHYDROXYBUTANES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230001001-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | BCL2 307/4885PTPN1 2395/4885CAPN1 1355/4885 |
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | PLA2G4C, PLA2G4B, PLA2G4A | BCL2 2789/4885PTPN1 1814/4885CAPN1 1031/4885 |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | CDKL2, CDK2, CDKL1 | BCL2 2231/4885PTPN1 2030/4885CAPN1 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.